Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does BIMEKIZUMAB Cause Inability to afford medication? 9 Reports in FDA Database

Visibly Younger Skin in Weeks

Synevra Lift & Lock — Swiss peptide serum + nutrients. 60-day money-back guarantee.

Discover Synevra

According to the FDA Adverse Event Reporting System (FAERS), 9 reports of Inability to afford medication have been filed in association with BIMEKIZUMAB (Bimzelx). This represents 0.4% of all adverse event reports for BIMEKIZUMAB.

9
Reports of Inability to afford medication with BIMEKIZUMAB
0.4%
of all BIMEKIZUMAB reports
0
Deaths
1
Hospitalizations

How Dangerous Is Inability to afford medication From BIMEKIZUMAB?

Of the 9 reports, 1 (11.1%) required hospitalization.

Is Inability to afford medication Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for BIMEKIZUMAB. However, 9 reports have been filed with the FAERS database.

What Other Side Effects Does BIMEKIZUMAB Cause?

Psoriatic arthropathy (615) Psoriasis (400) Drug ineffective (293) Inappropriate schedule of product administration (238) Injection site pain (225) Product dose omission issue (163) Off label use (160) Oral candidiasis (146) Fatigue (138) Therapy interrupted (138)

What Other Drugs Cause Inability to afford medication?

LISDEXAMFETAMINE DIMESYLATE (913) RIFAXIMIN (672) APIXABAN (479) BREXPIPRAZOLE (355) FLUTICASONE\SALMETEROL (323) ARIPIPRAZOLE (280) AMPHETAMINE ASPARTATE\AMPHETAMINE\DEXTROAMPHETAMINE SACCHARATE\DEXTROAMPHETAMINE (274) VIBEGRON (267) CERTOLIZUMAB PEGOL (238) SITAGLIPTIN (227)

Which BIMEKIZUMAB Alternatives Have Lower Inability to afford medication Risk?

BIMEKIZUMAB vs BIMEKIZUMAB-BKZX BIMEKIZUMAB vs BINIMETINIB BIMEKIZUMAB vs BIOFLAVONOIDS BIMEKIZUMAB vs BIOTIN BIMEKIZUMAB vs BIPERIDEN

Related Pages

BIMEKIZUMAB Full Profile All Inability to afford medication Reports All Drugs Causing Inability to afford medication BIMEKIZUMAB Demographics